Page 88 - ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hemogenyx Pharmaceuticals PLC Announces 03 Jun 2021, 01:43 GMT+10 Hemogenyx Pharmaceuticals plc ( Hemogenyx Pharmaceuticals or the Company ) U.S. Approval and Issuance of CDX Antibody Patent LONDON, UK / ACCESSWIRE / June 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office. The patent was issued as Patent Number US 11,021,536 B2 (https://tinyurl.com/yspjv89w). This patent covers a method of use of a bi-specific antibody ( CDX ), one of the Company s original and lead product candidates, for conditioning bone marrow/hematopoietic stem cell ( BM/HSC ) transplantation. It also covers a composition of matter (a subset of sequences) of monoc

New yorkUnited statesUnited kingdomCity ofVladislav sandlerTrademark officeLondon stock exchangeEuropean union withdrawalFinancial conduct authorityCompany us approvalHemogenyx pharmaceuticalsHemogenyx pharmaceuticalUnited states patentPatent numberAbuse regulationMarket abuse regulation